Literature DB >> 12789343

A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression.

Vasiliki Anest1, Julie L Hanson, Patricia C Cogswell, Kris A Steinbrecher, Brian D Strahl, Albert S Baldwin.   

Abstract

NF-kappaB is a principal transcriptional regulator of diverse cytokine-mediated processes and is tightly controlled by the IkappaB kinase complex (IKK-alpha/beta/gamma). IKK-beta and IKK-gamma are critical for cytokine-induced NF-kappaB function, whereas IKK-alpha is thought to be involved in other regulatory pathways. However, recent data suggest a role for IKK-alpha in NF-kappaB-dependent gene expression in response to cytokine treatment. Here we demonstrate nuclear accumulation of IKK-alpha after cytokine exposure, suggesting a nuclear function for this protein. Consistent with this, chromatin immunoprecipitation (ChIP) assays reveal that IKK-alpha was recruited to the promoter regions of NF-kappaB-regulated genes on stimulation with tumour-necrosis factor-alpha. Notably, NF-kappaB-regulated gene expression is suppressed by the loss of IKK-alpha and this correlates with a complete loss of gene-specific phosphorylation of histone H3 on serine 10, a modification previously associated with positive gene expression. Furthermore, we show that IKK-alpha can directly phosphorylate histone H3 in vitro, suggesting a new substrate for this kinase. We propose that IKK-alpha is an essential regulator of NF-kappaB-dependent gene expression through control of promoter-associated histone phosphorylation after cytokine exposure. These findings provide additional insight into the role of the IKK complex in NF-kappaB-regulated gene expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12789343     DOI: 10.1038/nature01648

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  216 in total

1.  Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Linda D Hazlett
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Epigenetic regulation in alcoholic liver disease.

Authors:  Pranoti Mandrekar
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 3.  IκB kinase alpha and cancer.

Authors:  Shuang Liu; Zhisong Chen; Feng Zhu; Yinling Hu
Journal:  J Interferon Cytokine Res       Date:  2011-12-07       Impact factor: 2.607

4.  Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism.

Authors:  Cong Luo; Hai Jun Zhong; Li Ming Zhu; Xian Guo Wu; Jie Er Ying; Xiao Hong Wang; Wang Xia Lü; Qi Xu; Yong Liang Zhu; Jian Huang
Journal:  Mol Biol Rep       Date:  2011-12-30       Impact factor: 2.316

5.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

Review 6.  Epigenetic mechanisms in inflammation.

Authors:  D Bayarsaihan
Journal:  J Dent Res       Date:  2011-01       Impact factor: 6.116

7.  Blocking IKKα expression inhibits prostate cancer invasiveness.

Authors:  Rubi Mahato; Bin Qin; Kun Cheng
Journal:  Pharm Res       Date:  2010-12-30       Impact factor: 4.200

Review 8.  The human Mediator complex: a versatile, genome-wide regulator of transcription.

Authors:  Dylan J Taatjes
Journal:  Trends Biochem Sci       Date:  2010-03-17       Impact factor: 13.807

9.  Coordinated regulation of Nrf2 and histone H3 serine 10 phosphorylation in arsenite-activated transcription of the human heme oxygenase-1 gene.

Authors:  Paul D Ray; Bo-Wen Huang; Yoshiaki Tsuji
Journal:  Biochim Biophys Acta       Date:  2015-08-18

10.  Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis.

Authors:  L Andresen; V L Jørgensen; A Perner; A Hansen; J Eugen-Olsen; J Rask-Madsen
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.